PharmaTelevision - Amgen Spain: Success in Europe

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Amgen Spain: Success in Europe

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Jordi Marti, CEO at Amgen Spain. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss:

• Why Amgen decided to set up key centres in Spain

• Spain as a market for Amgen

• How Amgen's Spanish operation has changed in the last 20 years

• Spanish biotech's effect on Amgen's strategy

• How decentralisation in Spain can benefit Amgen

• Amgen Spain's future

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Why Amgen Inc decided to set up key centres in Spain.

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Barcelona at BioEurope. On this show I have Jordi Marti, who is CEO of Amgen Spainhere in Spain, welcome.

Jordi Marti:

Welcome, thank you.

Fintan Walton:

Jordi Marti, Amgen Inc is one of the most successful biotechnology companies out of the United States. Its history goes all the way back to the 70's and early 80's and today it's obviously a global company and its presence here in Spain is quite unique it's got a particular special position here you are based here in Barcelona you've also got offices in Madrid, so tell us the story about how Amgen Inc decided to invest here in Spain and to take Spain as one of its key centres?

Jordi Marti:

Yeah.In fact that it's an important year for us due to the fact that it our 30th anniversary from the global company because we started everything in 1980 and it's our 20th from the local affiliate perspective so that it's an elderly company from the biotech perspective but we are feeling really young from the perspective that we have a lot of projects for the future. The fact that Amgen Inc invested in Europe and we were one of the first countries that they developed all the business is obviously because that it is an important market for Europe and then at that time as I was telling to you in 1990 that we decided to have the base the company here in Barcelona, here mainly because as you probably know we have 50-50 pharmaceutical business between Barcelona Madrid so they are both a lot of tradition from pharmaceutical and science in Barcelona and that was the reason why Amgen Inc came here. In fact I it is my 19th anniversary in the company, so I am an elderly guy from this perspective not from other.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Jordi Marti

CEO

Jordi Marti is CEO of Amgen Spain . He has graduated in medicine, MBA from ESADE and PADE (senior management programme) from IESE; J. L.

Amgen Spain

Amgen Inc is an international biotechnology company headquartered in Thousand Oaks, California. Located in the Conejo Valley, Amgen Inc is the largest independent biotech firm. The company employs approximately 14,000 staff members including the 125 Allied-Barton Security staff and A-post personnel in 2007. Its products include Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar, Mimpara and Nplate. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.